Amicus Therapeutics (FOLD) 28 Feb 242023 Q4 Earnings call transcript

Great. Thank you. Didi [ph]. Good morning. Thank you for joining our conference call to discuss Amicus Therapeutics' full year 2023 financial results and corporate highlights. have Chief President Chief Business and we Officer; Chief Financial call, Dr. Martel, Sebastien Officer, today's Bradley and Campbell, Executive Officer, Leading Simon Harford, Chief Officer. Castelli, Jeff Development

is business, referenced on XXXX Reform prospects. X, Officer plans Q&A Joining the Chief statements make Act as relating slide our Mitchell Private meaning and Chief Officer.As Rosenberg, of of we Medical the for well Legal as and Dr. forward-looking Ellen our within may to Goldman, Litigation Securities

be as the be achieved, call and risks representation by not made that should by of our be out us wrong uncertainties. this statements will any be or affected known any inaccurate forward-looking Our or to regarded can may turn on forward-looking assumptions unknown by and make plans we all or statements might

are undertake obligation by after place not speak in call to reliance the the forward-looking are or and presentation any cautionary hereof.All date this to or to statement their only reflect conference circumstances on no qualified statements, events forward-looking to we statements revise which date update this entirety hereof. cautioned You undue and

over Commission.At we December a statements Campbell, you Form of year full Bradley statements Bradley? them, Exchange my with time, this forward-looking today Executive the the to and to ended and Chief XX, Securities Annual for For XX-K it's call uncertainties the to XXXX to later section be impact President may the filed Officer. the such risks forward-looking pleasure of and turn factors and that on risk and our discussion refer Report

call Day. conference before year Disease call. everybody, welcome, and falled to Thanks, Great. full our Rare XXXX This day our a year, Andrew,

we year's Amicus been to minute living people results, nearly the is our the and have important inception, before committed and behalf in theme patient rare been diseases. XXX the with I opportunity, to acknowledge of importantly, dedicated our This of access and million achieving has Rare global Rare communities the Disease whose as to with just voices into serving this So Disease equity health true heard. fighting health Rare advocating needs living work care a serves for collectively are for to those action to towards take not Community. condition.Since rare call ways, social dive equity and perhaps, in Community a on want day Disease for around Day to for a to I extraordinary medicines those people world the most

the me into commemorating for and progress am So I I we of business to just that, just join in and results Disease you highlight made year what global day pleased the very this global our important Community.So ask with last shift and Rare that outlook, our XXXX. of all me into financial across tremendous let start

this saw release, the you to highlight press team points to in detail. turn As several through over I'll key it morning's before more go I

the Galafold first, success. continues it and our performance, its cornerstone remains So of strong

the Galafold uptake We $XXX now X,XXX we in steady We and of and continued for XX,XXX treaters, and our see year, observe switch or driven treated patients.Just the major improved that primarily both trends and reminder, our a saw patient continue driver demand diagnosed starts to diagnosed demand XXXX newer continued was adherence geographies, living Fabry minute, XX% diagnosis and growth all initial compliance with a into of to disease, leading of untreated there Fabry starts, from strong to key year. to globally, and new perspective patients new finding XXXX.For who and to of more as to patient were Galafold and estimated patient people outperforming Fabry continues field net across We in populations beyond, Throughout Today, education very patients X,XXX we in see through there and continue million our as including visits the our between market take growth untreated. our years we sustained by representing which markets. are in-person year-over-year, penetration our XXXX, eight over indicators continue in in markets continuing put all treated team growth population, Galafold the in key were of be naive medical performance patients. have a and over to of with revenue are from end with guidance just continued of patients in patient than launch for XXXX expectations who translated to pleased expect rates are Galafold X,XXX the the XX%.Growth taking ago, switch at of that globally. Fabry full over our we

XX% with Opfolda constant expect and is the underway in when Pombiliti a has X,XXX XX% patients. great market treated also the untreated provide is three come, XXXX, another exchange will projected market launch more than rates.Second, great to time, grow for in and to increased almost Galafold at we start the of opportunity underlying So These the many, that growth largest Pompe to year years while global off has market to commercial including markets. to doubled many dynamics in the

give to continue strength with going indicators demand this ago at US, that to therapy.The performance we launch are launch. patient to continued not the on Our treatment, teams for the weeks scheduled this new UK color talked treatment progress have we we improve commercial continue XXX commercial for last we we're were new launch incredibly or Seven the shared initial far. confidence and the in significant And key we remain the the XX the pleased more about incredibly at and with and give JPMorgan, and including mid-quarter on said share how of physician can Germany, patients as in so that in made pleased time I updates, us but patients. conference,

Sébastien of by and we XXXX, on across we're European momentum reimbursement expanding countries, seeing from provide new anticipate patients naive Pombiliti will and commercial all into pricing expect.In in to increase growth markets. performing patients additional our Lumizyme, Nexviazyme the access number naive on where has and each we're our new of we the launch And on segments overall, year. continue switch the we're are Pombiliti of well, launches in off importantly, new to as great of well of progress see we'll continue Specifically, through further and patients, that will are that therapy, coming focus year. add in key through navigate and the switching process majority part weeks to for continues as markets.So to early the from three the an focus coming country-by-country as submissions whereas ongoing as on Nexviazyme Opfolda increasing commercial the majority our of latter additional seeing most US, coming in of well. regulatory and a Europe, and means Lumizyme the share, as countries proportionally rate We performance these the the all the but market to pleased as we on ex-US patients coming very markets, the as Opfolda, so of prescriptions to Throughout increasing patient color patients would that launch patient are in by indicators, additional we patients moment, the of and

we the We physicians as maintained a therapeutic strong Pompe of are choice position incredibly both on continue financial expansion incredibly real and of pleased launch for disease.Third, and global with challenging Pombiliti has to advance patients people Opfolda. options the execute be an providing and Galafold living for and Amicus to

XXXX, in pleased This delivered fourth as is in first as we over a obviously We of XXXX. in product look for deliver for supported disease in well time strategic as of the profitability company Amicus the to expense non-GAAP first promised, quarter we management share in XXXX non-GAAP biotechnology full as a key as our slide sales, are significant the first well of are by profitability prudent now significant milestones priorities quarter to to today combined out year space.Our that our laid evolution of billion X. the really we milestone rare the in $X.X

further are of launches give maintaining Fabry let Pompe strategic for double-digit successful sustaining on and including: the and and support finally, we out and on as priorities me launch commercial revenue XXXX, and strong number order Sébastien? again, to new of last disease, who our laid full we year, Pombiliti ongoing XX% Sébastien, that to key commercial our continuing focused call profitability.With year hand expenses advancing executing carefully to of financial growth over a our and our our at exchange XX% to successful non-GAAP achieve manage we As achieving investments Galafold our one, rates, position performance. Opfolda our leadership can studies throughout in month, constant scientific multiple that, now in medical highlights the

Thank the markets.Turning full for reached growth slide XXXX, by to demand, driven Good revenue to year. on Galafold for good On from XXXX more Galafold I'll in performance primarily you or you, by strong reported year slide was Bradley. start everyone providing morning leading patient call. on the details X. afternoon $XXX.X our X, our the with Galafold particularly million.

of XX% year XXXX, fourth that since patients all markets, global at reported at be in Galafold The the major revenue net efforts. in the strongest XXXX constant over of to the XX% Our or for to CER.We're growth year up demand new delivering continues year our quarter for XX% of $XXX.X pleased exchange was strength the commercial same strongly, or results Galafold globally highlight the in share patients with rates. period We operational full Galafold with strong XXXX. XXXX XX% added finished million,

the roughly has gives to are is UK, is growth of the over we many there put the more mentioned, year drivers long leading of to X,XXX than Galafold, amenable of markets ended this global the confidence more treated XX% US, as over demand XX% the captured of amenable global with But great countries good such that's market half share to product Galafold X which remain patient the biggest therapy. the on Brian and still patients on run.As of market Our patients. patients. treated Japan of share patients EU in the and the news

stronger populations. the Within switch mix, and in XX% uptake seeing is naive which naïve, global XX% we're about

segments.All for shares and market been high market on to So Galafold. diagnosed them our patients the longest and to that penetrate go diagnosed keep who countries those belief by to switch patients underpinned achieve plenty the exceed into over that and to newly in on is rates to adherence sustained on Galafold continue stay opportunity continue we of treated compliance and to where of still XX%. please as approved we that there's continue growing the Reiterating we've Galafold

a to growth typically ordering patterns due calls, the within year fluctuations, past the FX variety of rate on of contributing mentioned As uneven and is nonlinear.

US Additionally, and we've timing slightly seen the orders within due process in the expect we XXXX.So prior QX the that reauthorization continue come below to table. the in revenues and into historically QX to of

of we've this expect corresponds snapshot the and Galafold of the given On a for hand during the side XXXX. distribution Interestingly, the year. each the a full we historical of percentage years what provided quarter sales trend a of We right occur quarterly year. five the precisely to five-year to similar slide, would achieved after over year average last sales,

a of to there's slide significant XX% year Galafold QX sales So, and expect demand around Galafold.On segment the of the of for example, XXXX X, of be amenable decade. the global in we of for sales of to with be an patient and the current know $X mutations revenue we year growth full in reach that growth the to sustained potential the drivers. to up driven by patients as market growth We annual by key Fabry several anticipate beyond end made billion as

and to First, improved medical identification ongoing increase patient through screening education continuing diagnosis.

is know disease. under of rare diagnosed one most As the probably you

execution. So the amenable is more other continued for are be share the treated more for patients patients eligible commercial continuing market patients piece through of identified to Galafold.Second can Galafold's drive

that our most As XX% to has market. or we're market market amenable is seeing What we about XX% the to mature XX% Galafold can in of reach up noted, share. XX% global of currently

we highlighted from growth So Fabry into levels new reach population. that the is two significant robustly know coming this penetrating growing global the portion to Bradley market untreated with in a a there's well.Importantly, market as finding patients diagnosed share earlier, of and nine potential as

[indiscernible].And in Middle as X,XXX in newly about Just intellectual were within either provide in the for which markets Asia Pacific and and and here, markets East with through and continue patents important on before to addition some adherence We of patient in expect time on Galafold XXXX X,XXX patients or in for expanding support continue again XX to including programs. labels. XXXX Galafold well access intend protection education US reimbursement.Also on often the patients the physicians composition of broad to Galafold This reimbursed newborn and with to to and partnership naive provide coming globally make initiatives orange-bophystic any patents. to Europe that us treatments and into intelligence all of from we rights. exclusivity artificial individuals regions property solid a finding compliance We've matter our of through these the our opportunity beyond into and by to new to diagnostic of long these as progress time provides We'll XX Galafold supported There still enforce come. efforts the is and are some end screening been extended Galafold. other have where rates are to our successful we XX note the protect new

will Looking Galafold we and and on decade.Turning XXXX into slide a remain to Pombiliti well for long yield double-digit IP our outline We the protection expect progress provide global on now ahead company's steady our confident next launch we XX. Opfolda. Galafold throughout that with strong runway growth

three with and reported XXXX, At year, were So for year number and would Pombiliti said, from clinical rate access and the markets we our beginning and This revenue Opfolda and for engaged early prescribers in are of pleased of particular, see and with, been XXX continued be support Pombiliti US, roughly the who the what and the naive programs, continue switching to positive important all from Brad proportionally part patients a of and from seeing see the an switching business fourth as from reimbursement. feedback and of at demand very clinical all rate, with Nexviazyme exactly expanded have In both treatment, we from segments, products. anticipated, the $XX.X want proportional on of Outside million year we're or three population, say, Myozyme, as programs. to from and seeing a switching depth, ERTs XXXX, markets. XX% outreach a and had for increase XX our We've treating patient competitor therapy.As XX% access track the stage.Our with teams, has HCPs I seeing an were or other been highly treatment from our across and prescribers, breadth find full well studies million Lumizyme. launch $X.X our US, is stakeholders patients we as to core of growing to for this cross-functional naive all commercial approach, reached All full this have to continues quarter. progress and new at which majority Opfolda remaining as scheduled trial metric from not XXX new leveraged approximately we experienced or coming KOLs. onto We're switches treatment. about seen, we've to had the patients Myozyme, the of our of we're patients the in access we've three patients increase great of and focus.Finally, across means coming centers

demand. demonstrate and we've acceptance in respective and of on submitted. to the on and US, we are patient Pombiliti have well.Today, onto and with pleased We seen payers than with active Opfolda More discussions in as pricing the Germany, the been by building who momentum launched as already the patient and Pombiliti with we're many access the European conversations put the markets Medicaid with the the payers starting broad engaging dossiers have new positive highly XX Austria. large a formularies, year reimbursement strong, major team focus also and in experienced Opfolda. reimbursement securing and additional We're strong and also we're we're year, the In US, off start UK, their throughout Overall, EU. Medicare of have value of very the

And maximizing will across we and focus have launches of our great the confidence as strengths We in patients real at data, first regulatory I Pombiliti a with our launch. that, with Chief the position to on talent second studies living well XXXX, successful of the all Jeff? our be wave with ability make of countries, to timelines. depth pleased number course the we're of Gatseli, ongoing Development to in is our by difference the a in call on Opfolda the Officer, people of clinical of therapy disease. amicus over will clinical Jeff our us believe the to very summary, hand year-end.So, Amicus the gives Over as and experience discuss great Pompe for

morning, and access good evidence everyone. remind studies Opfolda for submissions. On to everyone Sebastian, we through our we execute regulatory build we that you, slide also clinical on the Thank XX, of through to continue continue commercial as ongoing expanding Pombiliti and body

now again registry open-label of to launch, engaging phase the we excited we the in once As Pombiliti segments in at have have Pompe regulatory even populations. here enrolling very was mechanism presentation study disease. the that Amicus marking Annual and February, of conference ongoing we begun with we an Treatment Award data differentiated lysosomal continue based various Amicus to we in made are importantly across XX label Pompe living pipeline. have amicus in many see or enter patients patient endpoints innovation, for diseases.Finally diseases throughout Symposium XXth or and regulatory difference of Diego. Amicus New to for much highlighted with note, studies open-label am highlighting World award submissions as had actually more generating and on to reimbursement have planned significant second ongoing and very for we children supporting that ahead.Through can companies community, expansions new younger Opfolda, multiple people ZIP approval globally.And we living have enroll scientific treatments achieve and ongoing for continue Pompe expect important but support Opfolda in into continued the process lives also that an RZELA our earlier the our a we Pompe which announce impact addition dossiers clinical across an and I action Symposium meaningful in of oral to for registry, appendix children this our the had World that evidence Pompe and and to was presence the need the in pipeline as year.For the obtained long-term these kids slide in XXXX honored important [ph] recognizes this disease opportunity that in Fabry and advancing into Pompe. stage we of achievements Of work Pombiliti posters geographies and the held study the submitting, rare San in living patient and approval.It's a with years on access and honor the the make We for the the these these with an in to infantile-onset the so provide our late-onset

call engineered financial I outlook. that, and We now our to guidance like next-generation of GAA turn focus and Chief the Harford, day Financial GLA for including to novel over Simon and continue on our our transgenes would and Simon? approaches delivery to Pompe the results, review Officer Fabry-Chaperone.With Fabry to

you, Thank Jeff.

and compensation, non-GAAP marketable to in SG&A depreciation.Net loss period, We of the define that million impairment exchange research our a geographic the full a at revenue fair year of to of December of year XXXX, consideration of million million assets, same growth for as full sold now $XXX decrease revenue remaining exchange I'm changes income million $XXX $XXX full XXXX. to for compared slide had revenue of expenses goods million we million XX%, the or within is contingent a $X.XX full loss year breakdown XX% operating with December total extinguishment consisted for in period. achieved XX%.On was year the million of global operating XXXX revenue year, over XX.X% XXXX and for that successful generated $XX million share as States increase year decreased on and Bradley United of slide fourth compared compared or to XXXX.In constant Our compared XXXX.At for to and excluding $XXX XXXX share XX. $XXX million, cash grew expenses rates. end the $X.X as XX% rates, guidance of and were total $XXX XXXX prior or of the to ending of $XXX XX, overview XX% XX% development the total and for Cost stock-based securities outside with a or refinancing XX% as XX%. expense per goal decrease of our Total which value per US. $X.XX to XXXX GAAP our period million strongly statement equivalents loss achieving Galafold net debt begins sales of to Blackstone which in prior per XXXX constant quarter of decreased revenue $XXX million in million on We very pleased million. compared financial to to expense of $XXX $XXX reduced year $X.XX including full the a non-GAAP following coming net of from as a expenses XXXX.Turning $XXX mentioned, XX, the a or share non-GAAP our to for the at the as the share operating in Cash, percentage a prior as a basis, X.X% was XX profitability, related

guidance non-GAAP million. year is $XXX XXXX $XXX Our expense million full to operating

ongoing in profit both have operating registry amidst We Fabry expense are study continue Pompeii Phase the to of activities, QX yet have as in year, generation a we There we profitability that Pompe, minimal of non-GAAP full as a Pombiliti. in countries continued XXXX commitments preclinical for we to XXXX. achievement XXXX kept non-GAAP revenue, to over our R&D expense expect in share achieve the in growth we as we combined And similar in reimbursed continue anticipate profitability as profit manufacturing minimal.As studies for investment with very launch saw to XXXX, about we billion X we me after well to by XXXX.Following well and is reminder, pleased of profitability for of in anticipate next is which including non-GAAP as a year build that.And throughout not year, in quarter-over-quarter that, QX prudent year well-over the first management.As let of QX think remarks. driven $X.X sequentially back to closing expected non-GAAP Bradley turn our the call the

significant a profitability.As world, launch Galafold as upon opening our up and XXXX, track supported who drive top-line non-GAAP inflection that, ongoing double-digit by at full said to of for continue major rare all work us Great. first I which in huge Sebastian, sustained performance tirelessly employees thanks Simon, for commercial our Jeff, to year the point. Amicus to building my revenue on diseases.Looking around will growth Thanks comments, a successful know I people the continue we is living global of puts well for with

for shareholders.With call our can of to delivering questions. open rare operator, living our the we positioned that, the creating strongly medicines with value to of thousands new advance mission world to continue to up are groundbreaking diseases and people now We around

question comes Anupam JPMorgan. And Rama from first instruction] [Operator our you. Thank of

question. Anupam. Hi. Kuno actually This for Thank the you Malcolm on taking is for

treatment? US benefit patients the stable seeing patients but regard pump are are from switches current pay, gaining who you from are just in So, progressing not that with or a to their clearly

Yes, great question.

bit a both. I of is think the answer little

know the by we of that thought some patients I've who should about say you that in or clinical well some through how know studies. they studies that stayed in patients be who not mouth relatives, patients participating word in those those were we've might new study. I heard heard, So, commercial patients

switch I'm to in were think eager phase then, that I of pumping patients, kind those we a therapies. up seeing their improving folder so of therefore on start were declining wanted different to where have I per the is which the others, indicated own for patients label regardless not And and know of who status.And the sure outcomes, of with hopes current as course, are drug

I seeing of think So, segments. those from both we're healthy dynamics

Thanks Brad. Great.

And TD moment next Ritu of our Baral Cowen. question Thank from comes you. question. One next for our

into morning, own that stable. a of Thanks of guys. are as little on any stable the field to definition see drill how do their Have question. for the that competitors, clinicians both on the and conference the in you the sort and definition Good now? on you spent lot of define during are guys head? that having yours see that seeing decliners, down decliner two it in To on that world, your the Brad a you taking clinicians population in conversations What further of your tools that using done and market decliners you symposiums the Sebastien, define time research defining segmentation of defining

I expect how may your quarter question, they are about launch, obvious, important that declining first as the I means talk us based for market question, to or that going patients declining end Ritu. some then the XX% through through for on what -- physicians to of Jeff that which you follow why be of determine and eligible markers either are maybe suddenly equally research more be the but or patients that Jeff historical a might think patient obvious sort of would well. would leading subtle to But that ways likely statement as of from clearly not of Thanks we Great Sure. much. Yes. the let part the or and will and Jeff declining. data. clinicians talk whether is defined a we use not talk tools is declining very which ways quarter into they on I'm patients that us stable is did that in may that be work are maybe so patients suggested perspective. what would a is the patients though therapy, which the phase, But improving indication remind patients, for would declining. look of in about stable.Although, are historically About improvement fact sort a declining patients, stable

And question Yes. Ritu. for you Thanks, thank the Brad.

what we a of see first on is asking but the like questionnaires, really in and And is measure motor lot biomarkers physician terms every do They So function function with some more come trials qualitative They parameters.So of less up follow look do at forced terms in for know you six is other biomarkers. the the the cadence do visit things just endpoints all, daily doing some of activities patient just during primary or minute of living. of depending of formal the they typically of in are patients walk their months. care site on capacity how they also of importance measures then the respiratory more Pompe team. that put vital treating quantitative the function the really and they course six may in motor cited are distance they what respiratory that on about

standardize are And doing. or and more overseeing learning of digging assessments we're we're have sort chunk trying those We start in patients out some in the countries. what stairs terms looking trying are is assessment options know their as is I as declining does looked more to Brad have the look physicians a of might tours declining, when clearly they're is for doing finding into vital much you deeper to community then those do we much harder of across do US, is in physicians it's XX% the many worsening. parameters. starting example it's climbing and that they're generally significant would different say patient it's how treatment tried of stable the of actually six who So across might is we very think assessment of XX% middle be And We're do walk as that holistic that of stable help while of XX%. that and having that patients in in differ capacity who perceived sites as mentioned of as that that minute hear to out is physicians really about to actually reporting at a And that forced patients they now estimate one more dig improving. XX% middle improving moving they things or to going to that stable, holistically. holistic time segment a stable fatigue who of or sleeping.So forward?So when

evolving an monitor how of symposium space to lot switching there's of definitely this related terms So been especially different physicians meetings in patients it's topic. a on and

I it's do it's eye we'll as used to two might this and really that one holistic patients define switch? an sort something they that how parameters on. or of they But when certainly said It's after So switch keep approach. not and status

the of would expectations Jeff. I think therapy. Ritu to is challenge us exciting for Thanks the that's really opportunity.

we said and Jeff patients. more have as choices for Now that physicians

Thanks. Great.

our moment question One question. of our Dae comes Ha And from you. Gon Thank for Stifel. next next

I'm should question on you them trial. us you going expanded Pompe, guys. guys can about have And onboarding is remind these XX if just patient I or you ever break taking of given so the the launches Good that down geographies? part Thanks XXXX how terms and new morning, access for in on clinical thinking about guess Thanks Did of cadence much. think what multiple on? that we the not our were of

roughly What Dae later at Remember, the of will in remind each the we first the US we then patients countries. thanks, said from had here launch and Germany Yes, UK launched in year. came which you Gon. and the the those JPMorgan equally is at

thought we of positive.The We're are that this which we very various in other was pulling of we're markets patients who trend those call and of continues. here So proportionately the in thing we on highlighted kind saw pulling the each treated the medications. from is

your there new provided the think of as increasing increasing from Nixviazyme. coming at that Europe in we're from an patients point as next to the naive seeing which the the I that patients because treated So makes rate color And here is patient important sense of patients well.And Nixviazyme Myozyme last as highlighted rate. increasingly in is Sebastian in in then the next US US is majority well are then not the we and of with starts majority we're segment both an are pulling Lumizyme our

and confidence the for momentum us so So new things the of building those continued all year net great and first us over months the launch. the a year faster two versus the in then months to gives patient acquisition of last of course point launch

anticipate on any of that cadence growth of US kind ex-US But visibility the this year? you versus

Yes.

such think you'll coming market larger see US just see start the States. in to the I more patients you'll United on is a because

the that's we'll that I will markets. have you'll typically carry I to volume bring a bigger us what start see think that point. play that various markets think is see The through on to patients will and more just out. And

very you much. Thank Excellent.

And Thank Schwartz, you. our moment Joseph question. Leerink question our for comes Partners. from One next next

interesting from on you're Thanks the It's and so much congrats Lumizyme. that Nexviazyme and switches progress. getting more

terms that you So terms color that the sub-segments be you improving. And in why of could give of those not might would be? any to in give Thank of that I us if just think talk proportion yeah, of us deemed about Maybe was might be dynamic color be you. some helpful. each that wondering,

Thanks Joe. Yeah.

we've the coming this of we're versus as as patients Jeff States in on. medication into continued how said Nexviadyme.So too to the has in time I hard no. we those think physicians be that think early what markets.I days, but boy, they're maybe are what going we've described the on into patients questions penetrating has launched one more big been I much really Nexviazyme is the everybody and are what a had year it of and and still you what seen really is, the United was And next in seen where know doing have next from they're think those majority it's you'll markets sticky longest, -- that fact, focused patients are

patient to how that's am or a question how question And and said, for I And drive think doing? as of a you for stable And is carefully those I I so think am drug, we're a choice physicians what that if for have they're medication. better of, be which expectations may outcomes.So more to declining, And their really it's it's that outcomes. patients about don't I performing they current chance challenge challenge looking my question a lot therapy. excited on? Jeff with really on to those are expectations.And where think a

so I of switches Nexviazyme, the the we've some we a Lumizyme seen why although Lumizyme the of patients that's far, in patients patients from of US majority well.And switching getting well. We're patients again So then with US naïve think outside still are on market. our majority new we're Nexviazyme. majority the Lumizyme, patients getting are as next getting Nexviazyme although are we a getting where majority it's We're switching as from and

will we So really dynamics of think are those all continue. healthy and

Great.

they Just self and severe are it that more States to satisfied people to, be at harder selecting follow-up patients the to patients might all Nexviazyme switch. Lumizyme more are it be United indicate indicate that essentially if I on and might in could. be that there could or Does on

case. don't that's I necessarily think the

improving about the or physicians an again, necessarily think those physicians where XX% we more that's a Lumizyme patients patients opportunity. that started I how about look the and going to real of switch those I of research of I Nexviazyme am when don't we that think It's I or have XX% patients have patients said i.e. medication XX% market patients segment really doing a did are or market. just be of estimate for a, declining of in talked who would stable period are we think we it's that's initially. the phase. likely mode time.And at And kind about of a to that

Very helpful. Thank you.

Jeff. Thanks,

Thank you. our our question for moment And from comes next One of Ellie Merle UBS. question. next

congrats taking And the question. guys the progress. on Hey thanks for

rate. could Just have the increasing something at seeing targeting in you written of specific seeing Or it I more proportion in for starts like trials? increasing if new pay that physicians? a you're And you as an deepening full physicians prescriber of or base you're you of income a already of sites possibility here? guess involved were prescribing Thanks. is or already the of mentioned in terms Are what from those talk terms little of that centers the numbers data, these similar a clinical key prescriptions that bit script the

Yeah. Great question, Ellie.

the call breadth depth. seeing increasing both on as we're So and mentioned Sebastian

of you So asked. it's kind both what of

and writing involved trials of already are participated have who in Trial prescriptions as in numbers I Germany US now of both continuing write well, been particular clinical seeing prescriptions write physicians to program in improving. weren't to in are in or then the prescriptions. we're the But who the the expanding centers those that the So AIMS starting the UK are segments would Clinical all know Program. so of centers the

prescriptions were do already so all continued to so. have writing And and they

yes so far. dynamic think I really So healthy

what And XXX proportion color reimburse any the guess I of then patients you of mentioned these JPMorgan on just at them? that are already

days I commercial infusion about already go as this prescription point takes And to that at XX Yeah, a them of it reimbursed. would say reminder to are time. majority from in

thing added that the States. great.And process of be But to January which December possibility other still process. means patients commercial their got we're formularies the course, who is So seeing patients continuing the the call, the more highlighted the to as prescriptions people newer in funnel in more continue and we going quickly to to more that we're add through may that and is in unfold into in see more we as the are United

as XX That would through sit might And to days. range. XX where we progress with trend launch. as we we well in around sort to overtime where could the so down same number started day you to continue we Galafold we down that which as saw expect was remember today winnowed And of the that come it is then

much. so Thanks Great.

the One Thank from And of Morgan Jeff our Stanley. question. you. for next comes next Hung moment question

should them still expect you apply think my potential seasonal question. you do Thanks. to I going the trends similarly? is the QX. it given maybe much taking talked Galafold know past seen think early? patterns QX the Or fairly that doesn't Thanks I for you've would this unfold. and year the mean, to that you in move How for with probability about we about as seasonal from launch

question. good Yeah,

probably too the soon to tell. answer is I think

of a I think phenomenon is momentum think the and more year. get year, throughout a would we in experience the expect launch to the to build more countries I add patients with course you which year, as you over and continue as natural physicians

to provide I answer are early to going so there as color we tell, is the able And guess, too forward.

in Of just momentum with year it's could the larger. course, we'll given to share you a you. general build expect think throughout I that But

you. Thank

for moment of question One Kluska our Kristen from next comes Cantor our Fitzgerald. And you. question. next Thank

growth Hi, been XX% from good patient everybody. XXXX diagnosis has really morning, The XXXX. growing to impressive. Fabric

the the So, recent including postpaid thinking since we from part launches? of in of market see some with how your on this therapies growth growth about own. the Curious might the you're market new came numbers

are are typically more Kristen. right see which Thanks Yes. a involved options more out therapeutic companies it's you And there. is phenomenon think when when I

you think in I focus Diagnosis & see do to Treatment. and tend increased

originally would of remark. you that maybe in the quite is XX of evidence literature. fact significant as believed more surprised of diagnosed in years that's details driver also Jeff And to share We some -- last significantly at reported not be. I Pompe's although than part as while can in what the Fabry growth seen wouldn't all the here, was under we prevalent if So sort be the is of have

just of maybe that benefit over diagnosis and about from from data So from Yes. excuse newborn to little time. high-risk believe bit screening talk increased should us kind would that lead also and Pompe the me a screening

and Also of importantly initiatives there. few rare low There's education better a across newborn in screening is better importantly and doing and other diseases. to countries One Thanks, for Brad, tools a our leading the the physicians better importantly is Kristen. cost Yeah. genetic US. diagnostic many in diagnosis testing dynamics question and thanks

a lot is is the for find that whole the can family.Pompe then extra disease and Pompe benefit of think and is it's Fabry. dominant one patient more an and The disease. fact Fabry you I So X-linked of similar you in recessive screen a

it CK similar to XX,XXX XX,XXX When screening studies look find Fabry. themselves to Many muscular newborn both independently just more than have as Apex know estimate weakness is dystrophy well Pompe each be need the elevated as limb-girdle or of in symptoms. of you or of looking but XX,XXX. patient levels, siblings Pompe was type at in the thought with actual one you people more So them Pompe one classically to you and like

times to thought. than three what more common has two So been

diagnose new X-linked patients expect we bit significant in do factor are diagnostic initiatives drive some of patients being of of lot sort still that having and So that underlying Pompe a of certainly helping the left a helping underlying ramped be as more of patients.I think but up lot to will that little education because diagnosed multiple companies coming growth well. us with factors therapy that Fabry onto same in diagnosed help a definitely is just of

you. Thank

you. And question. Richter Sachs. our question from next Salveen for Goldman our of moment comes Thank One next

our Shrinachal Hi for on for question. this is for [ph] Thank you taking Salveen.

Opfolda and Opfolda, your and you. slides Medicare in you is the mind see on focus publish XXXX for in of number when Or and mentioned on payer this therapy Medicaid? do a to Pombiliti target You maximize patients number there to in coverage have Thank and is for particularly Pombiliti expect the in that aspect that you there.

the just repeat I'm sorry can I you that? missed the question. I part one, first second got of it

– of Opfolda. on you the target end XXXX? of part there that asked Pombiliti therapy want on you mind and first in that that the maximize number In have to a Is given patients the force number I to focus your Sure. and achieve by I training

Great question.

this course, the we year early just launch given we've I targets. said we're internal in we of As that at launch. the think point, think guidance this it's fact still at give before, part of own a can't our the I But point but have

color. as for the in on continue on and mentioned soon think number rampAs report the sure as continue to -- Sebastien question. I'll I good already prudent for will we'll seen patients I'm Medicaid. and flavor in adding have as formularies So basis guidance process it be your and patients year, number we wouldn't weeks quarterly done. therapy of going And Medicare of into the to And from able will have news the is guidance to that give Yes, a to more of both you first more to over year, being particular payer have a provide yet, to we few it in accepted through revenue we and a be relates addition major a second give increase next as to more clarity we

and patients are And government so getting accepted both private process. through and patients insurance being

you. Thank

Thank our next question. Gil you. for And Needham. moment next comes our One from Blum question of

you Thank Gil. our for for on [ph] taking question. Ethan is this Hi

second. Galafold? to penetration to are you in patients partnership do your Thank with for advances think driving learning general a Moving recent identifying you. AI the OMX How Fabry and more and important machine in and further market for

Yes, great Jeff can but color give on collaboration. then I'll question. start more that that

starting a learning and intent have on color I and the little a impact We're doing But that. maybe, the of what think that Jeff to really that major And again, what partnership, that to different outcome of that Fabry. disease there? industry-wide diagnosing, phenomenon. excited I'm particular is we're the will and will on I already think OMX an in give bit be in but wide machine partnership with hopefully of out But patients. of see see all some sorts of

for the Thanks question. Yes.

actually provider.So cusp see type midyear, or you So record And of medical it and and of the programs may consent it that development And symptoms you on.We're outgrowth kind just disease on record you the the that an the well being a with health different should know And about Fabry around it excited with through flag by within very the the bunch initiatives find that that we're be within very basically in other can in February of it. offered don't create that health in also know to by to people then disease how globe. could could we potentially system country center approach, really job. certain could of the excited did. patients of good through their Fabry testing healthcare patients tested into so we're opting similar this people have very are on of very a scan you like is getting a that States. a have looks with can this particular, know a AI, and of disease that care health we published people And actually that fingerprint potentially, all and a many really system globe X-linked the people electronic records given how of large family testing OMX around records AI in we sort or around medical have approach living and medical do when the well here academic then Fabry because find the help those here algorithm

of kind have care don't to single every health You screen system.

similar We see see done And diseases other for there for going that similar Fabry, are to if well. programs Pompeii well. only successful already is there's shown like has valuable if, be could as to look been to certainly actually as works a that other it's in approach not used and initiatives and systems and this

Thank you.

have conference That was your great day. a question. last Thank and today's This call you. concludes